SCHEMBL6468540

SCHEMBL6468540

O=C(c1ccc(Cl)cc1)N1CCN([C@@H]2CN(c3nc(C(F)(F)F)cc(C(F)(F)F)n3)C[C@H]2O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.48
▸ GBA1 P04062 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ SLC6A7 Q99884 2/20 0.42
▸ MGLL Q99685 2/20 0.42
▸ RHOC P08134 3/20 0.41
▸ RHOA P61586 3/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ PKM P14618 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ AKR1C3 P42330 1/20 0.39
▸ HCRTR1 O43613 1/20 0.39
▸ HCRTR2 O43614 1/20 0.39
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1257628 1.00 HSD17B10 (0.48) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL1256185 0.95 HSD17B10 (0.44) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL2400509 0.93 GBA1 (0.51) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL1257267 0.93 GBA1 (0.51) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL2403331 0.93 GBA1 (0.51) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL6467687 0.91 HSD17B10 (0.42) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL1257439 0.91 HSD17B10 (0.42) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL1258594 0.91 HSD17B10 (0.42) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL6468259 0.91 HSD17B10 (0.42) HSD17B10GBA1MAPTSLC6A7MGLL
SCHEMBL6467632 0.90 RHOC (0.42) HSD17B10GBA1MAPTSLC6A7RHOC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140364420-A1 SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-12-11 — — US disclosed
US-20130123270-A1 SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-05-16 — — US disclosed
US-8168788-B2 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-05-01 — — US disclosed
US-20110237601-A1 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-29 — — US disclosed
US-7880002-B2 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-01 — — US disclosed
US-7880002-B2 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237601-A1 Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists ACKR3, CCR5, CCR2 HSD17B10 3762/4885GBA1 2527/4885MAPT 4863/4885
US-20140364420-A1 SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS ACKR3, CCR5, CCR2 HSD17B10 3762/4885GBA1 2527/4885MAPT 4863/4885
US-20130123270-A1 SUBSTITUTED PIPERAZINYL-PYRROLIDINE COMPOUNDS USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS ACKR3, CCR5, CCR2 HSD17B10 3762/4885GBA1 2527/4885MAPT 4863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback